Onartuzumab

Published

dm+d

Unassigned

New Medicines

Gastric or gastroesophageal cancer, Her2-, MET, inoperable, combination therapy

Information

Licence extension / variation
Genentech
Roche

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Jul 14: Development of onartuzumab for treatment of metastatic HER2-negative gastric cancer has been discontinued [1].

Category

Humanised monovalent monoclonal antibody that blocks Met signalling in cancer cells
In England during 2010, there were 5,910 new cases of malignant neoplasm of the stomach including oesophageal junction [2]
Gastric or gastroesophageal cancer, Her2-, MET, inoperable, combination therapy
Intravenous infusion

Evidence based evaluations